Perimenopause Starts in Your 40s. Most Women Are Never Told That.
Dr. Jeff Kindred, DOPerimenopause doesn't show up on a blood test. Most women are never told this.
When labs come back normal in your early 40s, the assumption is that nothing hormonal is happening. That assumption is wrong — and it's one of the most common ways this transition gets missed.
Hormone levels during perimenopause fluctuate too unpredictably to be captured in a single draw. This isn't a flaw in the testing. It's how perimenopause works. The Menopause Society and other major professional bodies are explicit: routine hormone testing is not recommended for diagnosing perimenopause. It's a clinical diagnosis — made through careful history, symptom pattern, and age.
“Your hormones are fine” isn't reassurance. It's a normal result in a transition that standard labs weren't designed to detect.
What Perimenopause Actually Is
Perimenopause is the hormonal transition leading up to menopause — and it can begin 7 to 10 years before your final period.
Menopause is defined as 12 consecutive months without a menstrual period. The average age in the United States is 51. But the transition toward that point — perimenopause — is a long runway. For many women, that means symptoms beginning in their early-to-mid 40s. Sometimes even late 30s.
During perimenopause, estrogen and progesterone don't decline in a smooth, predictable line. They fluctuate erratically — spiking and dropping unpredictably over months and years. This is a significant part of why the symptoms can feel so confusing and hard to pin down.
It's not “in your head.” It's biology.
The Symptoms That Often Get Missed
Most people associate perimenopause with hot flashes and irregular periods. Those are real — but they're often not the first symptoms, and many women go years experiencing the following before menstrual changes even begin:
- Brain fog — difficulty concentrating, word-finding trouble, mental fatigue
- Sleep disruption — difficulty falling asleep, staying asleep, or feeling rested
- Anxiety or low mood — new or worsening, often without an obvious trigger
- Fatigue — despite adequate sleep and exercise
- Weight gain or redistribution — particularly toward the abdomen
- Decreased libido
- Joint pain and body aches
- Heart palpitations
- Changes in skin texture, elasticity, or dryness
- Vaginal dryness, discomfort during sex, or urinary symptoms — including urgency and recurrent UTIs — often beginning years before the final period
- Increased recovery time after exercise — something that also drives what we see in high performers who feel like they're suddenly declining
These symptoms often appear years apart, in isolation, and without an obvious hormonal connection. They get attributed to stress, thyroid dysfunction, depression, or simply “getting older.”
Sometimes those are contributing factors. But the hormonal component frequently goes unexamined.
Why This Is a Clinical Diagnosis — Not a Lab Result
FSH and estradiol — the hormones most commonly tested when women mention these symptoms — fluctuate dramatically and unpredictably throughout perimenopause. They can be elevated one week and completely normal the next. A single draw tells you almost nothing useful about where someone is in the transition.
This is not a fringe opinion. The Menopause Society, ACOG, and other major professional bodies explicitly do not recommend routine hormonal blood tests for diagnosing perimenopause.5 The diagnosis is made clinically — through a careful history of symptoms, their timing, and a woman's age.
Labs do have a role, but a different one: we check thyroid function (which can mimic many perimenopausal symptoms), metabolic and cardiovascular markers, and sometimes testosterone — not to diagnose perimenopause, but to rule out other contributors and get a full picture of overall health.
The problem in a standard practice isn't that the wrong labs are ordered. It's that there's no time to take a real history. Without a physician who knows you over time, the pieces don't get assembled into a coherent picture.
A Note on Who Gets Heard — and Who Doesn't
Women's health symptoms have historically been underevaluated and dismissed. Research consistently shows that women wait longer for diagnoses, receive fewer referrals, and are more likely to have physical symptoms attributed to psychological causes.
Women of color face additional, compounding disparities. Studies show that Black women experience earlier and more symptomatic menopause transitions on average — with higher rates of vasomotor symptoms and greater impact on quality of life — and are significantly less likely to be offered or prescribed hormone therapy.1
This is a real and documented gap in care. A relationship-based, individualized model of medicine is better positioned to address it. When your physician knows you — your baseline, your history, your concerns — you are not being evaluated against a population average. You're being evaluated as yourself.
The Medicine 3.0 Approach to Perimenopause
Traditional medicine is designed to diagnose and treat disease.
Medicine 3.0 asks a different question: What is happening now, what is the trajectory, and what can we do to improve how this person feels and ages over the next 20–30 years?
For women in perimenopause, that approach includes:
A thorough symptom history
Mapping when symptoms started, how they've evolved, and how they're affecting energy, performance, mood, sleep, and quality of life — not just checking a box for “hot flashes: yes/no.”
Labs to rule out other causes and assess overall health
Not to diagnose perimenopause — that's done clinically. But to check thyroid function, metabolic health, cardiovascular risk markers, and other contributors that deserve attention in midlife regardless.
An honest conversation about HRT
The evidence on hormone replacement therapy has shifted substantially. The Women's Health Initiative study from 2002 — which created widespread fear around HRT — has been significantly reanalyzed. For appropriate candidates, modern estrogen-based HRT has a favorable risk-benefit profile and meaningful benefits for symptom management, bone density preservation, cardiovascular health, and cognitive protection.2
Timing matters. The evidence is strongest for women who start HRT within 10 years of their final period or before age 60 — often called the “window of opportunity.” Starting during perimenopause or early menopause, when vascular and neurological tissues are still estrogen-responsive, appears to carry meaningfully better risk-benefit ratios than starting decades later.
This doesn't mean HRT is right for every patient. It means the decision deserves a real, individualized, informed conversation — not a reflexive “the risks are too high.”
Local vaginal estrogen — the most underused treatment in women's health
Separate from systemic HRT, and worth knowing about on its own: local vaginal estrogen therapy is one of the most evidence-supported, safest, and most overlooked treatments available for perimenopausal and menopausal women.
Applied locally, it addresses the genitourinary syndrome of menopause (GSM) — vaginal dryness, painful sex, urinary urgency, and recurrent UTIs — with minimal systemic absorption. It is considered safe for the vast majority of women, including many who are not candidates for systemic hormone therapy. Yet it is dramatically underprescribed, and many women are never told it exists.8
If urinary or vaginal symptoms are part of your picture, this is a specific, concrete conversation worth having — and one that often doesn't happen in a standard visit.
An integrated plan
HRT is one tool. Strength training, sleep optimization, metabolic management, stress modulation, and targeted supplementation are others. The right combination depends on the individual — her symptoms, her history, her cardiovascular risk, and her goals.
What About Supplements?
This comes up often, and I want to be direct about it: the evidence for most supplements marketed for perimenopausal symptoms is weak, inconsistent, or simply absent.
That doesn't mean patients don't find some of them helpful — anecdotal experience is real and worth acknowledging. But I'm not going to recommend something I can't point to good data for.
- Phytoestrogens (soy isoflavones, red clover): The most studied option. Some trials show modest reduction in hot flash frequency; many others show no meaningful benefit. Not harmful for most people, but not something with strong, consistent evidence.6
- Black cohosh: Mixed trial results, unclear mechanism, rare but documented cases of liver toxicity. The evidence doesn't support confident recommendation.
- Magnesium: Reasonable general evidence for sleep quality. Not perimenopause-specific, but low-risk and worth discussing for the right patient.
- Evening primrose oil, maca, and most others: Insufficient evidence to recommend.
For moderate-to-severe symptoms, HRT remains the most evidence-supported and effective treatment available for the right candidates.
Why This Matters Beyond Symptom Relief
Estrogen is not only a reproductive hormone. It plays a broader role in long-term health that often goes unappreciated:
- Cardiovascular health — estrogen supports vascular function. Its decline is associated with increased cardiovascular risk, which is one reason heart disease in women rises sharply after menopause.3
- Bone density — estrogen decline accelerates bone loss. The decade around menopause is a critical window for preserving skeletal strength.
- Brain health — estrogen has neuroprotective properties. Research suggests early intervention during the perimenopausal window may support long-term cognitive health.4
- Metabolic regulation — insulin sensitivity changes with estrogen decline, contributing to visceral fat accumulation and metabolic risk.
- Muscle and connective tissue — estrogen plays a role in collagen integrity, joint health, and muscle recovery.
The decisions made in this decade matter.
The Relationship Difference
Perimenopause is not a single conversation or a single intervention. It evolves over years. Symptoms shift. What works at 42 may need adjustment at 46.
This is exactly the kind of longitudinal, attentive care that a fragmented system is not built to deliver. And it's exactly what a concierge model is designed to provide.
When your physician knows your baseline, your history, your goals, and your life — the conversations are different. More efficient. More precise. You are not starting from zero at every visit.
If This Resonates
If you're a woman in your 40s and something feels off — even if you've been told your labs are normal — trust that signal.
At Hi,Finch Health, we take women's hormonal health seriously. We have the time to listen, the tools to evaluate comprehensively, and the relationship-based model to support you through a transition that can span a decade.
If you'd like to learn more about our concierge medicine membership and whether it might be a good fit for you, click below.
BOOK YOUR INTRODUCTORY CONSULTATION WITH DR. KINDRED HERE
References
- Crandall CJ, et al. Disparities in menopause characteristics and management. Menopause. 2017. PubMed
- Manson JE, et al. Menopausal hormone therapy and long-term mortality. JAMA. 2017. PubMed
- Mendelsohn ME, Karas RH. Estrogen and the cardiovascular system. Climacteric. 2013. PubMed
- Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk. Neuroscience. 2006. PubMed
- Harlow SD, et al. Stages of Reproductive Aging Workshop +10. Menopause. 2012. PubMed
- Lethaby A, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database. 2013. PubMed
- The Menopause Society. Menopause Practice: A Clinician's Guide. 2022. menopause.org
- Portman DJ, Gass ML. Genitourinary syndrome of menopause. Menopause. 2014. PubMed
